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Esophagus, Gastric and Duodenal Ulcer Disorders
A265
LYMPHOCYTIC ESOPHAGITIS: A SINGLE TERTIARY CENTER’S
EXPERIENCE WITH THIS EMERGING CLINICAL ENTITY
C. Shams, M. Co, M. Cappell

Background: Various disorders can produce esophagitis. Lymphocytic esophagitis
(LE) has emerged as another clinical entity responsible for esophagitis symptoms.
Although increasingly reported pathologically, the clinical characteristics of LE have
not been well characterized.
Aims: The present study extends the clinicopathologic characterization of LE by
comprehensive analysis of 30 affected patients and identifies specific clinical
presentations significantly associated with LE.
Methods: Thirty patients were identified from January 2000-December 2016 that
satisfied diagnostic criteria for LE by lower esophageal biopsy; (1) high concentration
of intraepithelial lymphocytes and (2) few granulocytes (ratio of
lymphocytes:granulocytes >50:1). Controls, selected from patients undergoing
esophagogastroduodenoscopy (EGD) during the same time interval were divided into
two groups; control I (N=30) included patients matched for age and sex, and control-II
patients (N=30) who were matched for age, sex, and endoscopic indication. Baseline
characteristics of the 30 patients with LE were contrasted with the two control groups.
Results: Patients with LE were predominantly female and Caucasian. Average BMI
was 25.7 ± 5.7. 63% had reflux similar to control I and II patients (57% and 50%
respectively; p=>0.05). 17% of the study group had a diagnosis of Crohn’s disease
versus only 7% in control I and 3% in control II, but these differences were not
statistically significant. In the study group, 20% had autoimmune disease versus 7% in
each of the control groups (p=<0.05). Surgical history including esophageal, gastric or
colonic surgery was not statistically different, but there was a higher incidence of
gastric and colonic surgeries in the study group with 17% versus 3% in control I and
7% in control II. Proton-pump inhibitor (PPI) use was prevalent among all three
cohorts with no significant difference between the three groups. Half of the study
patients experienced dysphagia. This incidence was significantly greater than that for
control I (p= 0.03) or control II (p= 0.04). Study patients had esophageal endoscopic
findings of esophageal rings (27%), irregular z line (30%), and reflux esophagitis
(27%), and these rates were significantly more than those of the controls. The
majority of the gastric endoscopic findings showed erythematous nonbleeding
gastropathy (53%, p=0.8). Lymphocyte counts in the study group averaged 80.9 ±
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59.2/hpf, while that of control group I was 24.2 ± 22.9/hpf and that of control group II
was 26.7 ± 26.4/hpf. Eosinophils were rarely detected (eosinophil count=0.4 ±
1.1/hpf).
Conclusions: It remains to be seen whether LE represents a novel pathological
phenotype or is a variation of known chronic conditions. However, providers should
consider in the evaluation of patients presenting with chronic dysphagia.
Downloaded from https://academic.oup.com/jcag/article/2/Supplement_2/521/5381324 by guest on 22 February 2022

Funding Agencies: None

